Rankings
▼
Calendar
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
Q2 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$9M
Gross Profit
$9M
100.0% margin
Operating Income
-$92M
-1061.5% margin
Net Income
-$90M
-1034.9% margin
EPS (Diluted)
$-1.05
QoQ Revenue Growth
+18.6%
Cash Flow
Operating Cash Flow
-$70M
Free Cash Flow
-$83M
Stock-Based Comp.
$16M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$284M
Stockholders' Equity
$1.1B
Cash & Equivalents
$271M
← FY 2016
All Quarters
Q3 2016 →
ALNY Q2 2016 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
